1. ALLA AKTIER
  2. NYHETER
  3. COMBIGENE

Combigene

Nyheter Combigene Nyheter alla bolag

Interim report January – March 2024 for CombiGene AB (publ)

MARKN.

January – March 2024
Net sales: TSEK 326 (2,168).
Other operating revenues: TSEK 1,042 (0).
Profit from financial items: TSEK -14,194 (-14,617).
Earnings per share: SEK -0.72 (-0.74).
Cash and cash equivalents: TSEK 90,318 (120,506).

Events during the period
• CombiGene regains the global rights to the epilepsy project CG01 as the termination period of the collaboration and
license agreement between the two companies has expired.
• CombiGene discontinues the preclinical development of the lipodystrophy project CGT2.
• CombiGene’s epilepsy project CG01 has been granted patent in two new countries, Australia and India.

Events after the end of the period
• CombiGene initiates collaboration with Västra Hamnen Corporate Finance.

Contacts

CombiGene AB (publ)
Peter Ekolind, CEO
Phone: +46 (0)8 35 73 55
peter.ekolind@combigene.com

www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
+46-8-357355 info@combigene.com

About CombiGene

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.
 
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB.

Please read Ingeneious, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Ingeneious and press releases are available at www.combigene.com

Attachments

CombiGene Q1 2024 EN

Datum 2024-05-17, kl 09:00
Källa MFN
Bifogade filer
CombiGene Q1 2024 EN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!